AGIO
NASDAQ · Biotechnology
Agios Pharmaceuticals Inc
$27.53
-0.58 (-2.06%)
Financial Highlights (FY 2026)
Revenue
37.25M
Net Income
687.60M
Gross Margin
88.6%
Profit Margin
1,845.9%
Rev Growth
-27.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.6% | 88.6% | 41.3% | 41.3% |
| Operating Margin | 1,817.6% | 1,635.9% | -6.6% | -5.9% |
| Profit Margin | 1,845.9% | 1,753.6% | -5.7% | -6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 37.25M | 51.13M | 198.27M | 200.72M |
| Gross Profit | 33.00M | 45.30M | 81.91M | 82.92M |
| Operating Income | 677.08M | 836.48M | -13,033,249 | -11,761,210 |
| Net Income | 687.60M | 849.47M | -11,344,752 | -12,565,080 |
| Gross Margin | 88.6% | 88.6% | 41.3% | 41.3% |
| Operating Margin | 1,817.6% | 1,635.9% | -6.6% | -5.9% |
| Profit Margin | 1,845.9% | 1,753.6% | -5.7% | -6.3% |
| Rev Growth | -27.2% | -27.2% | -2.9% | -8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 267.01M | 273.20M |
| Total Equity | — | — | 1.12B | 1.12B |
| D/E Ratio | — | — | 0.24 | 0.24 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 689.45M | 899.08M | -15,767,673 | -13,652,238 |
| Free Cash Flow | — | — | -7,306,109 | -10,881,640 |